Drug Profile


Alternative Names: GABRA5 negative allosteric modulator (NAM) - Roche; RG-1662; RO5186582

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche
  • Class Antidementias; Oxazoles; Pyridines; Small molecules; Thiamorpholines
  • Mechanism of Action GABA A alpha 5 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Down syndrome; Neurological disorders
  • Preclinical Schizophrenia

Most Recent Events

  • 01 Nov 2016 Preclinical trials in Schizophrenia in Switzerland (PO) before November 2016
  • 01 Nov 2016 Roche plans a phase IIb trial for Schizophrenia (Adjunctive treatment) in USA (PO) (NCT02953639)
  • 27 Sep 2016 Phase-II clinical trials in Neurological disorders (In adults, In the elderly) in Spain (PO) (EudraCT2015-003227-66) (NCT02928393)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top